Pronounced cytostatic activity and bystander effect of a novel series of fluorescent tricyclic acyclovir and ganciclovir derivatives in herpes simplex virus thymidine kinase gene-transduced tumor cell lines

Gene Therapy

Volumn 9, Issue 17, 2002, Pages 1173-1182

  Balzarini, J ^a   Ostrowski, T ^b   Goslinski, T ^b   De Clercq, E ^a   Golankiewicz, B ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

Author keywords

Acyclovir; Fluorescent nucleoside analogues; Ganciclovir; Gene therapy; Herpes simplex virus; Thymidine kinase; Tricyclic purine nucleoside analogues

Indexed keywords

ACICLOVIR; ACICLOVIR DERIVATIVE; ANTIVIRUS AGENT; CYTOSTATIC AGENT; GANCICLOVIR; GANCICLOVIR DERIVATIVE; PURINE NUCLEOSIDE DERIVATIVE; THYMIDINE KINASE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BODY FLUID; BREAST CARCINOMA; BYSTANDER EFFECT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOSTASIS; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG UPTAKE; FLUORESCENCE ANALYSIS; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; LIPOPHILICITY; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; TUMOR CELL LINE; VIRAL GENE DELIVERY SYSTEM;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; FEMALE; FLUORESCENT DYES; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; OSTEOSARCOMA; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ANIMALIA; HUMAN HERPESVIRUS 1; MURINAE; SIMPLEXVIRUS;

EID: 0036711794     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301779     Document Type: Article

References (19)

1. Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds
2. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
3. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
4. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir
5. The treatment of ovarian cancer with a gene modified cancer vaccine: A phase I study
6. In situ use of suicide genes for cancer therapy
7. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
8. Human gene marker/therapy clinical protocols
9. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified
10. Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study
11. 9-[(3-[18F]-fluoro-1-hydroxy-2-propoxy) methyl]guanine ([18F]-FHPG): A potential imaging agent of viral infection and gene therapy using PET
12. Crystal structures of the thymidine kinase from herpes simplex virus type-1 in complex with deoxythymidine and ganciclovir
13. Efficacy of anti-herpetic drugs in combined gene/chemotherapy of cancer is not affected by a specific nuclear or cytoplasmic compartmentation of herpes thymidine kinases
14. Differential intracellular compartmentalization of herpetic thymidine kinases (TKs) in TK gene-transfected tumor cells: Molecular characterization of the nuclear localization signal of herpes simplex virus type 1 TK
15. Establishment of mutant FM3A murine mammary carcinoma cell lines transformed with the herpes simplex virus type 1 thymidine kinase gene
16. Comparative activity of various compounds against clinical strains of herpes simplex virus
17. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells
18. Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy
19. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1, 3-dihydroxy-2-propoxymethyl) guanine, and other antiherpetic drugs on tumor cells transfected by the virus type 1 or type 2